Company / R&D Expense
Mereo BioPharma Group plc R&D Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$17.8M
FY2025
5-year range
$17.4M / $20.9M
FY2023-FY2025
Trend
-15.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$18M in FY2025.
Remained stable around $18M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d expense decreased 15.1% year-over-year.
Company context
Key Data Points
- Altman Z-Score -7.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.8M | -15.1% |
| FY2024 | $20.9M | +20.2% |
| FY2023 | $17.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 27, 2026